Gan & Lee Pharmaceuticals (603087.SH): GLR2037 tablet Phase I clinical trial completed first subject dosing.

15:39 03/04/2026

Ganli Pharmaceutical (603087.SH) announced that the company's independently developed GLR2037 tablet is undergoing Phase I clinical trials in China, and recently successfully completed the first subject dosing. GLR2037 tablet is a type 1 chemical new drug developed independently by Ganli Pharmaceutical, which is a androgen receptor-protein degrading targeted hybrid (ARPROTAC). The indication for this clinical trial is advanced prostate cancer.

Gan & Lee Pharmaceuticals (603087.SH) announced that the company's self-developed GLR2037 tablet is undergoing a Phase I clinical trial in China, and has successfully completed dosing for the first subject recently. GLR2037 is a novel class 1 chemical drug developed by Gan & Lee Pharmaceuticals, which targets the androgen receptor-protein degradation chimera (ARPROTAC). The indication for this clinical trial is late-stage prostate cancer.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.

Industrial: Market fluctuations intensify. How are various types of funds moving?

Chairman Zheng Jiachun increased his holding of CHOW TAI FOOK (01929) by 30,000 shares at a price of approximately HK$10.76 per share.

Chairman Pan Binze increases his holdings in TEXWINCA HOLD (00321) by 2.76 million shares at a price of approximately 1.21 Hong Kong dollars per share.